Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Combination therapy with AT(1)-receptor blockers.

P Trenkwalder¹

¹Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, Germany. Peter.Trenkwalder@t-online.de

Journal of Human Hypertension

|July 26, 2002

Summary

Achieving strict blood pressure targets often requires combination therapy for hypertension. Candesartan cilexetil plus hydrochlorothiazide offers superior efficacy and tolerability compared to other combinations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on the management of arterial hypertension].

Der Internist·2019

Same author

Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension.

Blood pressure·2017

Same author

[Antihypertensive treatment after stroke: target blood pressure and treatment recommendations].

Deutsche medizinische Wochenschrift (1946)·2012

Same author

[High blood pressure in the morning].

MMW Fortschritte der Medizin·2012

Same author

[Acute stroke in hypertensive patients: treat hypertension slowly and check blood pressure continuously].

MMW Fortschritte der Medizin·2011

Same author

Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination.

Blood pressure. Supplement·2009

Area of Science:

Cardiovascular Medicine
Pharmacology

Background:

Current hypertension guidelines advocate stringent blood pressure targets, which are difficult to achieve with monotherapy.
Combination therapy is often necessary for effective hypertension management, requiring drugs with complementary actions and good tolerability.

Purpose of the Study:

To evaluate the efficacy and tolerability of combination antihypertensive therapies.
To compare the effectiveness of candesartan cilexetil/hydrochlorothiazide with other treatment regimens.

Main Methods:

Clinical trials comparing combination therapies (e.g., candesartan cilexetil/hydrochlorothiazide, losartan/hydrochlorothiazide) against monotherapy and each other.
Assessment of blood pressure reduction and control rates.
Evaluation of drug tolerability.

Main Results:

Candesartan cilexetil (16 mg) plus hydrochlorothiazide (12.5 mg) demonstrated superior blood pressure lowering compared to monotherapy.
This combination proved more effective than losartan (50 mg) plus hydrochlorothiazide (12.5 mg) in reducing and controlling blood pressure.
Combination therapies maintained placebo-like tolerability profiles.

Conclusions:

Combination therapy, particularly with an AT(1)-receptor blocker and a diuretic, is a rational and effective strategy for achieving stringent blood pressure targets.
Candesartan cilexetil/hydrochlorothiazide offers significant advantages in efficacy and tolerability for hypertension management.

Related Experiment Videos